Liquidia Corp. LQDA

What this company does

Liquidia Corporation operates through its wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC, and generates revenue through the sale of YUTREPIA (treprostinil) inhalation powder and, under a promotion agreement with Sandoz Inc. dated August 1, 2018, through a share of profit from the sale of Sandoz's generic treprostinil injection in the United States. As of December 31, 2025, the company employed 216 employees. It operates from a 45,000 square foot facility in Morrisville, North Carolina, where it designs, formulates, and manufactures engineered drug particles using PRINT particle fabrication lines, and in June 2025 it entered into a lease for a new 70,131 square foot facility in the same city. YUTREPIA, its inhaled dry-powder formulation of treprostinil designed to enhance deep lung delivery and achieve higher dose levels than the labeled doses of other inhaled therapies, was approved by the FDA for the treatment of both PAH and PH-ILD in May 2025 and was launched in June 2025. Treprostinil Injection is a fully-substitutable generic treprostinil for parenteral administration in the United States; the company holds exclusive rights to conduct commercial activities for the product and works jointly with Sandoz on commercial strategy, while Sandoz retains all other rights and holds the Abbreviated New Drug Application for it. The company was incorporated in Delaware on June 17, 2020.

Written from the business description in LIQUIDIA CORPORATION's annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.